|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||90.00 - 92.73|
|52 Week Range||18.15 - 134.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||144.43|
Stock Monitor: AnaptysBio Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on Nabriva Therapeutics PLC (NASDAQ: NBRV ) (“Nabriva”). ...
AnaptysBio dipped Tuesday despite trial results showing its peanut-allergy drug improved symptoms in nearly half of adult patients tested.
The week is now well underway and there are a couple of major developments in the biotechnology space, both of which are related to the release of clinical trial data and both of which have translated to some real volatility in the market capitalization of the companies to which they relate. The two companies in […] The post Here’s What’s Moving AnaptysBio and Biohaven Pharmaceutical appeared first on Market Exclusive.
Gainers: AnaptysBio Inc (NASDAQ: ANAB ) shares are up 8 percent on news of positive top-line proof-of-concept data for ANB020 in peanut allergy patients. Sears Hometown and Outlet Stores Inc (NASDAQ: SHOS ...
46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500 mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with ...
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...
NEW YORK, March 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: AnaptysBio Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Cellular Biomedicine Group Inc. (NASDAQ: CBMG ...
ANB020 Top-Line Phase 2 a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018. ANB019 GPP and PPP Phase 2 Studies to be Initiated During 2018. SAN DIEGO, ...
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.
SAN DIEGO, Feb. 17, 2018-- AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
SAN DIEGO, Feb. 07, 2018-- AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical